VTYX: Ventyx Biosciences, Inc Price to Sales
High R&D expenditures and patent protection for TYK2 inhibitors create a significant barrier to entry for Ventyx Biosciences (VTYX). The price-to-sales valuation clearly demonstrates the asset's dynamics, while shows the current value of the metric. Growth potential is driven by high demand for selective therapy; however, fierce competition in immunology and clinical phase risks may dampen investor interest.
Ventyx Bio (VTYX) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Equity Ratio Ventyx Biosciences|VTYX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Ventyx Biosciences, Inc|VTYX - Company Total Debt|Debts to Book Value Ventyx Bio|VTYX - Company Long-Term Liabilities|Company Short-Term Indebtedness Ventyx Biosciences|Intermediate Coverage Ratio ventyxbio.com
- financial results and valuation multiples details:
VTYX - Net Profit|Expected Profit Ventyx Biosciences|VTYX - P/E Multiple|Market Cap to Projected Earnings Ventyx Biosciences Inc.|VTYX - Price/Earnings to Growth Ratio|Company Value to EBITDA Ventyx Bio|VTYX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Ventyx Biosciences|VTYX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months ventyxbio.com|VTYX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Ventyx Biosciences
- issuer revenue and sales details:
Summary company analytics:VTYX - ventyxbio.com
For Ventyx Biosciences (VTYX), which attracts leading immunologists through a stock option system, the price-to-sales chart reflects market expectations for the commercialization of innovative treatments. This multiple, calculated by dividing market capitalization by total revenue, measures the cost per unit of revenue, allowing investors to assess whether the assets are overvalued or undervalued relative to the issuer's actual cash inflows.
Who Ventyx Biosciences competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA: Market Cap to Revenue|PTGX: Price-to-Revenue Ratio|IMVT: P/S Multiple|Price to Sales kiniksa.com (KNSA)|Price-to-Revenue Ratio Grifols|Market Cap to Revenue Ratio ADPT (Adaptive Biotech)|Market Cap to Revenue CLDX (Celldex)|Market Cap to Sales Volume AUPH|BioCryst - Market Cap to Revenue|veratx.com (VERA) - Price to Sales|DNTH: Market Cap to Revenue|PHVS (Pharvaris NV) - Market Cap to Revenue Ratio|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|Price-to-Revenue Ratio PHAR|P/S Multiple NKTR|Price-to-Revenue Coefficient Upstream Bio, Inc.|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Immunome Bio (IMNM) - Price to Sales|GOSS - Price-to-Revenue Ratio|Price-to-Revenue Coefficient kalvista.com KALV|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharma|SVRA (Savara Corp) - P/S Multiple|Rigel Corp (RIGL) - Price-to-Revenue Coefficient|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene ENGN|RAPT: Market Cap to Revenue Ratio|Aerovate - P/S Multiple|Aclaris Therapeutics, Inc (ACRS) - Market Cap to Revenue|KYTX: P/S Multiple|Price to Sales tizianalifesciences.com (TLSA)|Price-to-Revenue Ratio Cabaletta Bio|Theratechnologies, Inc. (THTX) - Price-to-Revenue Coefficient|Market Cap to Revenue AVTX (Avalo Therapeutics Inc.)|Price-to-Revenue Ratio ELDN (Eledon Pharmaceuticals, Inc)|Agenus - Market Cap to Revenue|Market Cap to Sales Volume CLYM (climbbio.com)|ZURA: Market Cap to Revenue|Price to Sales aTyr Pharma Inc|ADAG (adagene.com) - Market Cap to Revenue|Market Cap to Revenue Ratio IMA|Price-to-Revenue Ratio Shattuck Labs Inc|Equillium Bio - Price-to-Sales Ratio|P/S Multiple CNTB|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ATRA (Atara Bio)|P/S Multiple InflaRx NV IFRX|XFOR - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ACET (Adicet Bio)|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|BRNS (Barinthus Bio) - P/S Multiple|P/S Multiple Kezar Life Sciences Inc|Market Cap to Revenue SABS (SAB Biotherapeutics)|AKTX (akaritx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Price-to-Revenue Coefficient Q32 Bio Inc (QTTB)|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Market Cap to Revenue XTLB|P/S Multiple Bolt Bio|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|Aditxt Inc. (ADTX) - Price to Sales|GRI: Market Cap to Revenue|XRTX: Price-to-Revenue Ratio|HIND: P/S Multiple|Price to Sales Revelation Biosciences Corp (REVB)|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|Market Cap to Revenue CALI (CalciMedica, Inc.)|Market Cap to Sales Volume AFMD|Allakos - Market Cap to Revenue|HOOKIPA Pharma, Inc. (HOOK) - Price to Sales|IGMS: Market Cap to Revenue|ITOS (iteostherapeutics.com) - Market Cap to Revenue Ratio|OCEA (Ocean Biomedical) - Market Cap to Revenue|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
